Last reviewed · How we verify
Anavip
At a glance
| Generic name | Anavip |
|---|---|
| Also known as | Antivenin Crotalinae (pit viper) equine immune F(ab)2 |
| Sponsor | Instituto Bioclon S.A. de C.V. |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab, (PHASE2)
- Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anavip CI brief — competitive landscape report
- Anavip updates RSS · CI watch RSS
- Instituto Bioclon S.A. de C.V. portfolio CI